Psyence BioMed Secures Regulatory Approval for Nature-Derived Psilocybin in Phase IIb Cancer Adjustment Disorder Trial
Key Insights
The Bellberry Human Research Ethics Committee (search) has formally approved PsyLabs (search)' nature-derived psilocybin product (NPX5 (search)) for use in Psyence BioMed's ongoing Phase IIb clinical trial targeting adjustment disorder (search) in cancer (search) patients.
The double-blind, randomized trial will enroll approximately 87 participants across multiple Australian sites to evaluate two therapeutic doses of psilocybin against a low-dose comparator, combined with structured psychotherapy.
This approval strengthens Psyence BioMed's position as one of the few vertically integrated psychedelic companies with GMP manufacturing capabilities and approximately $9.5 million in cash reserves to execute its clinical strategy.
Psyence Biomedical Ltd (search). (Nasdaq: PBM) has received formal approval from the Bellberry Human Research Ethics Committee (search) (HREC) to use PsyLabs (search)' nature-derived psilocybin product (NPX5 (search)) in its ongoing Phase IIb clinical trial evaluating psilocybin-assisted psychotherapy for adjustment disorder (search) in patients with cancer (search). The approval marks a pivotal advancement for the vertically integrated biopharmaceutical company's clinical program and reinforces its strategic positioning in the emerging psychedelics sector.
Regulatory Milestone Advances Clinical Program
The HREC approval followed comprehensive review of updated clinical documentation, including the amended protocol, investigator brochure, and participant information materials reflecting the transition to PsyLabs (search)' psilocybin formulation. The authorization applies to all participating study sites, including Empax Centre (search), Mind Medicine Australia Clinic (search), and Paratus Clinical Research (search) in Melbourne.
"We are extremely pleased that PsyLabs (search)' nature-derived psilocybin product has now been formally approved for use in our Phase IIb study," said Jody Aufrichtig, CEO of Psyence BioMed. "This is a pivotal advancement in our clinical program and a defining step in our long-term strategy. By incorporating what we believe is the best-in-class GMP compliant psilocybin product on the market – developed entirely within our vertically integrated structure – we are reinforcing supply-chain control, manufacturing excellence, and scalable production capacity that will drive future commercial success."
Phase IIb Trial Design and Timeline
The approved amendment confirms PsyLabs (search)' psilocybin as the investigational product in the double-blind, randomized, low-dose comparator-controlled clinical trial. The Phase IIb study will enroll approximately 87 participants and evaluate two therapeutic doses of psilocybin against a low-dose comparator, combined with structured psychotherapy.
With multiple sites activated and recruitment underway, the study remains on track to deliver top-line results in 2026. The company has also begun planning the activation of additional clinical sites to further accelerate patient recruitment and advance the Phase IIb program.
Vertical Integration Strategy
The approval highlights Psyence BioMed's evolution toward becoming one of the few vertically integrated psychedelic enterprises with multiple assets across drug and clinical development. With an investment in PsyLabs (search), significant clinical assets, and cash reserves of approximately $9.5 million, the company positions itself as one of the most differentiated companies in the emerging global psychedelics sector.
"Having our psilocybin formulation cleared for clinical use is a transformative moment for PsyLabs (search)," said Tony Budden, CEO of PsyLabs. "It reflects years of scientific, regulatory, and manufacturing preparation to ensure our product meets the highest standards for purity, repeatability, and patient safety. We are proud to support Psyence BioMed's mission to bring safe, nature-derived psychedelic therapies into regulated medicine."
Manufacturing and Quality Standards
PsyLabs (search) operates from an ISO 22000-certified facility audited by the British Standards Institution, ensuring the highest standards of safety and traceability. The company is federally licensed to cultivate, extract, and export psilocybin mushrooms and other psychedelic compounds including psilocin, mescaline, ibogaine, and dimethyltryptamine (DMT) to legal medical and research markets.
The company has successfully exported psilocybin products to Canada, the UK, Portugal, and Slovenia, and supplies purified extracts to its UK-based CMO partner. PsyLabs (search) is expanding its product pipeline to include ibogaine and other next-generation psychedelics.
Market Position and Financial Strength
This approval further strengthens Psyence BioMed's competitive positioning as one of the few companies globally with access to ethically sourced botanical raw materials, GMP manufacturing capabilities, and a fully aligned clinical development network. The company is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq.
With approximately $9.5 million in cash reserves and no debt, Psyence BioMed is positioned to leverage its strengthened vertical integration as clinical-grade psilocybin moves into Phase IIb trials. The company is dedicated to addressing unmet mental health needs, particularly in palliative care, through an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments.